A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 30, Issue 10, 2002, Pages 645-650

  Ritchie, D S ^a   Szer, J ^a   Roberts, A W ^a   Shuttleworth, P ^a   Grigg, A P ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Bone marrow transplantation; Continuous infusion; Etoposide; VP 16

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BUSULFAN; CLONAZEPAM; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; FOLINIC ACID; GANCICLOVIR; IMMUNOGLOBULIN; MESNA; METHOTREXATE; MORPHINE; OPIATE; PROPANTHELINE BROMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CARDIOTOXICITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LEUKEMIA; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MOUTH DISEASE; MUCOSA INFLAMMATION; NEUTROPHIL; PARENTERAL NUTRITION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOCYTE; ADOLESCENT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MUCOSA; PATHOLOGY; PHASE 1 CLINICAL TRIAL; STOMATITIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOUS MEMBRANE; STOMATITIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036861335     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703698     Document Type: Article

References (25)

1. Tutschka PJ. Copelan EA. Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
2. Bandini G, Belardinelli A, Rosti G et al. Toxicity of high-dose busulphan and cyclophophamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant 1994; 13: 577-581.
3. Rosenthal MA, Grigg AP, Sheridan WP. High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. Leuk Lymph 1994; 14: 279-283.
4. Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 1991; 8: 489-495.
5. Zander AR, Berger C, Kroger N et al. High dose chemotherapy with busulphan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997; 3: 2671-2675.
6. Crilley P, Topolsky D, Styler MJ et al. Extramedullary toxicity of a conditioning regimen containing busulfan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 361-365.
7. Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating doses of etoposide with cyclphosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 1989; 4: 559-565.
8. Ratanatharathorn V, Karanes C, Lum LG et al. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 1992; 9: 49-55.
9. Geller RB, Myers S, Devine S et al. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone Marrow Transplant 1992; 9: 41-47.
10. Jerjis S, Roovers E, Muus P et al. Idarubicin to intensify the conditioning of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Bone Marrow Transplant 1998; 22: 13-19.
11. Kroger N, Zabelina T, Sonnenberg S et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 2000; 26: 711-716.
12. Kanda Y, Akiyama H, Tanikawa S et al. Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team. Am J Hematol 1996; 51: 265-268.
13. Jones RJ, Santos GW. New conditioning regimens for high risk marrow transplants. Bone Marrow Transplant 1989; 4 (Suppl. 4): 15-17.
14. Rosenfeld CS, Przepiorka D, Schwinghammer TL et al. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease. Exp Hematol 1991; 19: 317-321.
15. Mross K, Bewermeier P, Reifke J et al. Pharmacokinetics of high dose VP-16: 6-hour infusion versus 34-hour infusion. Bone Marrow Transplant 1994; 13: 423-430.
16. Herzig RH. High-dose etoposide and marrow transplantation. Cancer 1990; 67 (Suppl.): 292-298.
17. Thompson DS, Hainsworth JD, Hande KR et al. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol 1993; 11: 1322-1328.
18. Ahmed T, Engelking C, Szalyga J et al. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 1993; 12: 131-132.
19. Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288-1294.
20. Hoyt R, Szer J, Grigg A. Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells. Bone Marrow Transplant 2000; 25: 1285-1287.
21. Essell JH, Thompson JM, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulphan/cyclophosphamide. Blood 1992; 79: 2784-2788.
22. Holden SA, Teicher BA, Robinson MF et al. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother Pharmacol 1995; 36: 165-171.
23. Workman DL, Clancy J Jr. Phenotypic analysis of pulmonary perivascular mononuclear infiltrates that occur as a direct result of acute lethal graft-versus-host disease describes the onset of interstitial pneumonitis. Am J Pathol 1995; 147: 1350-1360.
24. Porter D, Boddy A, Thomas H et al. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study. Semin Oncol 1996; 23: 34-44.
25. Soni N, Meropol NJ, Pendyala L et al. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. J Clin Oncol 1997; 15: 766-772.